Term ends Nov 28, 2026 · Medium confidence
20-year base term ends Nov 28, 2026
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 7,858,609, US 8,022,054, US 8,618,087, US 9,056,116), so the cap could be lower.
Nov 28, 2006
Nov 28, 2026
Sep 27, 2016
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 2 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 28, 2006, when application 11/605,700, the earliest non-provisional in its chain, was filed (this one was filed May 11, 2015) | Nov 28, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,858,609, US 8,022,054, US 8,318,714, US 8,367,651, US 8,618,087, US 9,029,355, US 9,056,116, US 9,452,176) | resolves to Nov 28, 2026, no earlier than this term, so no change | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Nov 28, 2026 | Medium confidence |
This family
| US 8,022,054 | In force no later than Nov 2027 | no later than Nov 2027 |
| US 8,367,651 | In force Nov 2026 | Nov 2026 |
| US 8,318,714 | In force Nov 2031 | Nov 2031 |
| US 9,056,116 | In force no later than Nov 2026 | no later than Nov 2026 |
| US 8,618,087 | In force no later than Nov 2026 | no later than Nov 2026 |
| US 9,029,355 | In force Nov 2026 | Nov 2026 |
| US 9,452,176 | this patent Nov 2026 | Nov 2026 |
| US 11,071,740 | In force Nov 2026 | Nov 2026 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 2, 2015 Reel 36937, frame 986 | Shaw, Kenneth; Zhang, Mingbao | Marinus Pharmaceuticals | Assignment of Assignor's Interest |
| May 11, 2021 Reel 56206, frame 266 | Marinus Pharmaceuticals, Inc. | Oaktree Fund Administration, LLC | Security Interest |
| Oct 28, 2022 Reel 61580, frame 171 | Marinus Pharmaceuticals, Inc. | Sagard Healthcare Royalty Partners, LP | Security Interest |
| Feb 13, 2025 Reel 70204, frame 35 | Sagard Healthcare Partners Funding Company SPE 1, LLC | Marinus Pharmaceuticals, Inc. | Release of Security Interest |
| Feb 20, 2025 Reel 70278, frame 496 | Oaktree Fund Administration, LLC | Marinus Pharmaceuticals, Inc. | Release of Security Interest |
| May 15, 2025 Reel 71128, frame 703 | Marinus Pharmaceuticals, Inc. | Immedica Pharma US Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 7,858,609, US 8,022,054, US 8,318,714, US 8,367,651, US 8,618,087, US 9,029,355, US 9,056,116, US 9,452,176, ends no earlier than this term, so it caps nothing.